PRVA Stock Analysis: Buy, Sell, or Hold?
PRVA - Privia Health Group, Inc. Common Stock
$23.67
-0.19 (-0.80%)
▼
5d:
-7.18%
30d:
-11.94%
90d:
-4.75%
HOLD
LOW Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 06, 2026
3d
Get Alerted When PRVA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: PRVA shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: PRVA shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$36.84
Based on 9.7% avg growth
INTRINSIC VALUE TODAY
$22.87
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 21.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PRVA is currently trading at $23.67, which is considered oversold relative to its 30-day fair value range of $24.74 to $27.46. The stock's valuation (Forward PE: 21.6) is in line with its historical norms (21.2). At these levels, the market is pricing in 0.6% annual earnings growth.
Technical Outlook: Technically, PRVA is in a strong uptrend. The price is currently testing key support at $23.41. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $31.89 (+34.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PRVA is in a strong uptrend. The price is currently testing key support at $23.41. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $31.89 (+34.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$24.74 -
$27.46
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
86.2%
Protect Your Profits
Holding PRVA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 34.7% below Wall St target ($31.89)
- BULLISH: Expecting earnings turnaround to 0.6% growth with 25.8% revenue growth
- CAUTION: Recommendation downgraded due to -7.2% 5-day decline
Trading Range Analysis
30-Day Trading Range
$24.74 -
$27.46
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.97
(4.1%)
Support & Resistance Levels
Support Level
$23.41
Resistance Level
$27.13
Current Trend
Strong Uptrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
21.57
Wall Street Target
$31.89
(+34.7%)
Revenue Growth (YoY)
25.8%
Earnings Growth (YoY)
-33.3%
Profit Margin
1.0%
Valuation Premium vs History
+0.6% premium
PE vs Historical
21.6 vs 21.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.6%
(market-implied from PE analysis)
1-Year Target
$23.81
(+1%)
2-Year Target
$23.95
(+1%)
3-Year Target
$24.10
(+2%)
3-Yr Target (if PE normalizes)
(PE: 22→21)
PE COMPRESSION
$23.69
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.6, Growth: 15.4%)
$36.37
(+54%)
Base:
(SPY PE: 20.7, Growth: 15.4%)
$34.96
(+48%)
Bear:
(PE: 17.6, Growth: 15.4%)
$29.71
(+26%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (27x PE), but valuation improves significantly next year (22x PE) as earnings recover.
Forward PE: 26.53 | Forward EPS (Implied): $0.89
Bull Case
$28.58
(+21%)
Analyst growth 15.0%, PE expands to 27.9
Base Case
$23.67
(0%)
Market implied 0.0%, PE stable at 26.5
Bear Case
$18.11
(-24%)
Severe decline -15.0%, PE contracts to 23.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 02, 2026 6:11 AM ET
Data refreshes hourly during market hours. Next update: 7:11 AM
Data refreshes hourly during market hours. Next update: 7:11 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PRVA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
18
Sells
Net
INSIDERS SELLING
Recent Transactions
David Mountcastle
SELL
5566 shares
2026-04-02
David Mountcastle
SELL
6391 shares
2026-03-16
Parth Mehrotra
SELL
26509 shares
2026-03-16
Top Rated Health Information Services Stocks
Top-rated stocks in Health Information Services by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VEEV
Veeva Systems Inc Class A |
BUY
32 analysts |
$244 | 55 HOLD |
|
GEHC
GE HealthCare Technologi… |
STRONG BUY
21 analysts |
$90 | 53 HOLD |
|
PHR
Phreesia Inc |
STRONG BUY
15 analysts |
$14 | 49 HOLD |
|
HQY
HealthEquity Inc |
STRONG BUY
14 analysts |
$118 | 50 HOLD |
|
EVH
Evolent Health Inc |
STRONG BUY
14 analysts |
$6 | 50 HOLD |
Advanced PRVA Option Strategies
Professional options setups generated by AI based on today's PRVA price and gamma walls.
